|
ИСТИНА |
Войти в систему Регистрация |
ИСТИНА ЦЭМИ РАН |
||
Biodistribution of Modular Nanotransporter Carrying Auger Electron Emitter and Targeted at Melanoma Cells in Murine Tumor Modelстатья
Информация о цитировании статьи получена из
Web of Science,
Scopus
Дата последнего поиска статьи во внешних источниках: 27 марта 2018 г.
- Авторы: Vorontsova M.S., Morozova N.B., Karmakova T.A., Rosenkranz A.A., Slastnikova T.A., Petriev V.M., Smoryzanova O.A., Tischenko V.K., Yakubovskaya R.I., Kaprin A.D., Sobolev A.S.
- Сборник: Physics of Cancer: Interdisciplinary Problems and Clinical Application. American Institutes of Physics. AIP Conference Proceedings
- Том: 1882
- Год издания: 2017
- Издательство: AIP Publishing
- Местоположение издательства: United States
- Первая страница: 020078-1
- Последняя страница: 020078-4
- DOI: 10.1063/1.5001657
- Аннотация: Recombinant modular nanotransporter containing -melanocyte-stimulating hormone peptide sequence (MNT-MSH) as a ligand module was designed for nucleus-targeted delivery of cytotoxic agents into melanoma cells. MNT-MSH radiolabeled with Auger electron emitter (111In-NOTA–MNT-MSH) showed a high antitumor efficacy in mice bearing syngeneic melanoma after intratumoral (i.t.) injection. This study is aimed at evaluating the biodistribution of the radioconjugate in melanoma tumor model in vivo. 111In-NOTA–MNT-MSH was administered i.t. in C57Bl/6j mice bearing subcutaneously implanted B16-F1 murine melanoma cells, expressing high levels of MCR1. The tissue uptake of radioactivity was determined ex vivo by gamma-counter measurements. The intravenous route of administration did not provide a desirable level of radioactivity accumulation in the tumor, possibly, due to a high uptake of the transporter in liver tissue. After i.t. administration 111In-NOTA–MNT-MSH provided a high local retention of radionuclide, ranged from 400 to 350 %ID/g within at least 48 hours post-injection. MNT containing Auger electron emitter and alpha-MSH peptide as vector ligand could be a promising basis for radiopharmaceutical preparations intended for melanoma treatment.
- Добавил в систему: Соболев Александр Сергеевич